- Home
- GNTA vs MIST Comparison
GNTA vs MIST Comparison
Compare GNTA & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | MIST |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | Italy | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 176.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNTA | MIST |
|---|---|---|
| Price | $1.44 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 92.8K | ★ 10.1M |
| Earning Date | 03-30-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $0.63 |
| 52 Week High | $10.00 | $3.06 |
Technical Indicators
Market Signals| Indicator | GNTA | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 36.07 | 42.75 |
| Support Level | $1.28 | $1.90 |
| Resistance Level | $1.68 | $2.22 |
| Average True Range (ATR) | 0.17 | 0.33 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 27.42 | 33.20 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).